Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cell Cycle

• Publication date

  2014-05-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.29212PMID 24841718PMCID PMC4111704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

  2015cited by this paper
• ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.

  2014cited by this paper
• DNA Damage Response-Related Proteins in Gastric Cancer: ATM, Chk2 and p53 Expression and Their Prognostic Value

  2013cited by this paper
• Are DNA Repair Factors Promising Biomarkers for Personalized Therapy in Gastric Cancer?

  2013cited by this paper
• Mutation at Intronic Repeats of the Ataxia-Telangiectasia Mutated (ATM) Gene and ATM Protein Loss in Primary Gastric Cancer with Microsatellite Instability

  2013cited by this paper
• Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients

  2013cited by this paper
• Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.

  2013cited by this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cited by this paper
• Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Mitotic catastrophe: a mechanism for avoiding genomic instability

  2011cited by this paper
• The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Impacts of fluorouracil‐metabolizing enzymes on the outcomes of patients treated with S‐1 alone or S‐1 plus cisplatin for first‐line treatment of advanced gastric cancer

  2010cited by this paper
• Targeting homologous recombination repair defects in cancer.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Protein Phosphatase 6 Interacts with the DNA-Dependent Protein Kinase Catalytic Subunit and Dephosphorylates γ-H2AX

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

  2010cited by this paper
• ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

  2010cited by this paper
• The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

  2009cited by this paper
• Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Cellular radiosensitivity: How much better do we understand it?

  2009cited by this paper
• Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

  2008cited by this paper
• S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

  2008cited by this paper
• DNA repair deficiency as a therapeutic target in cancer.

  2008cited by this paper
• ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin.

  2008cited by this paper
• Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer.

  2008influential reference
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

  2008cited by this paper
• Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

  2008cited by this paper
• Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents*

  2007cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis

  2005cited by this paper
• Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

  2005cited by this paper
• Cancer risks and mortality in heterozygous ATM mutation carriers.

  2005cited by this paper
• Ataxia-telangiectasia, an evolving phenotype.

  2004cited by this paper
• DNA damage-induced activation of ATM and ATM-dependent signaling pathways.

  2004cited by this paper
• Ataxia-Telangiectasia-Mutated (ATM) Gene in Head and Neck Squamous Cell Carcinoma

  2004cited by this paper
• Short Communication Ataxia-Telangiectasia-Mutated (ATM) Gene in Head and Neck Squamous Cell Carcinoma: Promoter Hypermethylation with Clinical Correlation in 100 Cases

  2004cited by this paper
• Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression.

  2003cited by this paper
• TP53 and gastric carcinoma: A review

  2003cited by this paper
• ATM Mutations in Sporadic Lymphoid Tumours

  2002cited by this paper
• Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase.

  2002cited by this paper
• Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history

  2001cited by this paper
• Early Embryonic Lethality in PARP-1 AtmDouble-Mutant Mice Suggests a Functional Synergy in Cell Proliferation during Development

  2001cited by this paper
• LYMPHOID NEOPLASIA The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells

  year unknowncited by this paper

• Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

  2026cites this paper
• Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor

  2026cites this paper
• PARP inhibitors in gastric cancer: unlocking precision oncology

  2025cites this paper
• Genetic heterogeneity and key driver mutations in the preneoplastic and earliest stages of gastric cancer

  2025cites this paper
• Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies.

  2025cites this paper
• A Gene Expression Signature that Predicts Gastric Cancer Sensitivity to PARP Inhibitor Therapy

  2024cites this paper
• PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation

  2024cites this paper
• Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies.

  2024cites this paper
• Identification of neutrophil extracellular trap-driven gastric cancer heterogeneity and C5AR1 as a therapeutic target

  2023cites this paper
• Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

  2023cites this paper
• DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy

  2023cites this paper
• Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study

  2023cites this paper
• Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer

  2022cites this paper
• Signaling pathways and therapeutic interventions in gastric cancer

  2022cites this paper
• Identify Multiple Gene-Drug Common Modules via Constrained Graph Matching

  2022cites this paper
• Molecular pathogenesis and emerging targets of gastric adenocarcinoma

  2022cites this paper
• Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

  2022cites this paper
• Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.

  2021cites this paper
• Inhibitors of Nucleotide Excision Repair Decrease UVB-Induced Mutagenesis—An In Vitro Study

  2021cites this paper
• DNA Damage Repair Inhibitors—Combination Therapies

  2021cites this paper
• Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives

  2021cites this paper
• Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  2021cites this paper
• PARP inhibitors in gastric cancer: beacon of hope

  2021cites this paper
• The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice

  2021cites this paper
• Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges

  2021cites this paper
• Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

  2021influential citation
• Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinoma

  2021cites this paper
• Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair

  2021cites this paper
• Heterogeneous Responses of Gastric Cancer Cell Lines to Tenovin-6 and Synergistic Effect with Chloroquine

  2020cites this paper
• Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.

  2020cites this paper
• PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer

  2020cites this paper
• Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer

  2020cites this paper
• Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort

  2020cites this paper
• Targeting DNA Repair Pathways in Hematological Malignancies

  2020cites this paper
• The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.

  2020cites this paper
• BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.

  2020cites this paper
• ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738

  2020cites this paper
• Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms

  2020cites this paper
• ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

  2020influential citation
• Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers

  2020cites this paper
• ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer

  2020cites this paper
• PARP Inhibition in Cancer: An Update on Clinical Development

  2019cites this paper
• Exploiting DNA repair defects in colorectal cancer

  2019cites this paper
• DNA junction ligands trigger DNA damage and are synthetic lethal with DNA repair inhibitors in cancer cells.

  2019cites this paper
• Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

  2019cites this paper
• Novel Agents and the Future Perspectives

  2019cites this paper
• Development of an Immunohistochemical Assay to Detect the Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcinoma

  2019cites this paper
• Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase

  2019cites this paper
• New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy

  2019cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells

  2019cites this paper
• Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

  2019cites this paper
• Precision medicine in gastric cancer

  2019cites this paper
• Targeted and novel therapy in advanced gastric cancer

  2019influential citation
• Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.

  2019cites this paper
• Impact of liver kinase B1 on p53 and survivin and its correlation with prognosis in gastric cancer

  2019cites this paper
• Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients

  2019cites this paper
• State-of-the-art strategies for targeting the DNA damage response in cancer

  2018cites this paper
• BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.

  2018cites this paper
• Biomarkers for Homologous Recombination Deficiency in Cancer

  2018cites this paper
• Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

  2018cites this paper
• The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

  2018cites this paper
• ATM in breast and brain tumors: a comprehensive review

  2018cites this paper
• Emerging Therapies in the Management of Advanced-Stage Gastric Cancer

  2018cites this paper
• Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

  2018cites this paper
• Drug repositioning using drug-disease vectors based on an integrated network

  2018cites this paper
• Genomic loss of heterozygosity and survival in the REAL3 trial

  2018cites this paper
• Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition

  2018cites this paper
• Targeting ATM for Cancer Therapy: Prospects for Drugging ATM

  2018cites this paper
• Combined treatment with PI 3 K inhibitor BKM 120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID 1 A deficiency

  2018cites this paper
• Small Molecules in Oncology

  2018cites this paper
• Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma

  2017cites this paper
• Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.

  2017cites this paper
• AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

  2017cites this paper
• Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.

  2017cites this paper
• Systemic therapy for esophagogastric cancer: targeted therapies.

  2017influential citation
• PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas

  2017cites this paper
• Targeted Therapy and Immunotherapy

  2017cites this paper
• The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways

  2017cites this paper
• Second-line chemotherapy for patients with advanced gastric cancer

  2017cites this paper
• ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib1

  2017cites this paper
• PARP inhibitors as precision medicine for cancer treatment

  2017cites this paper
• BRCAness revisited

  2016cites this paper
• POLY (ADP) RIBOSE POLYMERA SE INHIBITORS FOR THE TREATMENT OF MALIGNANT PERIPHERAL NER VE SHEATH TUMOR

  2016cites this paper
• APRIN(PDS5B) et PALB2, deux protéines impliquées dans la réparation de l'ADN par recombinaison homologue et l'apparition de cancers

  2016cites this paper
• Gr upSM Novel Therapeutic Targets in Gastric Cancer

  2016cites this paper
• ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent

  2016cites this paper
• New advances in targeted gastric cancer treatment.

  2016cites this paper
• Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.

  2016cites this paper
• Targeting deficient DNA damage repair in gastric cancer

  2016cites this paper
• Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer

  2016cites this paper
• An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.

  2016cites this paper
• Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

  2016cites this paper
• Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor?

  2016cites this paper
• Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer

  2016cites this paper
• ATM Mutations in Cancer: Therapeutic Implications

  2016cites this paper
• Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine

  2016cites this paper
• Clinical significance and role of LKB1 in gastric cancer.

  2016cites this paper
• PARP inhibitor combination therapy.

  2016cites this paper
• ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis

  2016cites this paper